Clomiphene Citrate

Indie iOS and Android application adds AI-assisted laboratory PDF extraction as U.S. testosterone prescriptions exceed 11 million annually. My doctor told me my testosterone was 'in range' more than once before I learned the standard range is built for the average 80-year-old. MyTRTApp exists because biohackers deserve a real tool.” — Himanshu Batra, Founder of Sphnix, Inc. WASHINGTON, DC, UNITED STATES, June 5, 2026 / EINPresswire.com / -- My TRT App, an iOS and Android application developed by Sphnix, Inc., has released a public bloodwork analyzer and an 89-compound peptide and GLP-1 reference library. Both tools are available at mytrt.app and do not require account creation. The release follows several years of growth in the testosterone replacement therapy (TRT) and GLP-1 weight-loss markets. U.S. testosterone prescriptions grew from approximately 7.3 million in 2019 to more than 11 million in 2024, according to industry pharmacy data. In April 2026, the U.S. Food and Drug Administration published guidance noting that testosterone therapy may be appropriate for treating low libido in patients with idiopathic hypogonadism, expanding the population for whom the therapy is being considered. GLP-1 medications including semaglutide and tirzepatide have also moved into mainstream prescribing, often alongside hormone therapy. A subset of patients on these therapies — sometimes described as self-directed or as biohackers — track their own laboratory results, monitor biomarkers between scheduled clinical visits, and adjust protocols in consultation with their prescribers. LABORATORY PDF EXTRACTION The My TRT App bloodwork analyzer ( TRT bloodwork analyzer ) extracts more than 40 biomarkers from uploaded laboratory PDF files. Extracted markers include total testosterone, free testosterone, sex hormone-binding globulin (SHBG), estradiol, dihydrotestosterone (DHT), hematocrit, hemoglobin, prostate-specific antigen (PSA), luteinizing hormone (LH), follicle-stimulating hormone (FSH), thyroid-stimulating hormone (TSH), and standard lipid, metabolic, liver, and kidney panels. The tool uses Google Gemini Vision for optical character recognition. Free users receive one lifetime extraction; additional extractions are available to subscribers. A separate web tool, the Lab Snapshot Analyzer at mytrt.app/learn/tools/lab-snapshot, provides interpretation of six headline TRT markers in a browser without account creation. PEPTIDE AND GLP-1 LIBRARY The My TRT App GLP-1 and peptide library catalogs 89 compounds tracked by self-directed users, including semaglutide, tirzepatide, retatrutide, BPC-157, TB-500, human chorionic gonadotropin (hCG), anastrozole, clomiphene, MK-677, RAD-140, NAD+, GHK-Cu, MOTS-c, and melanotan. Each entry includes mechanism of action, reported half-life, documented effects, side-effect profile, and references to external research. The library is available on the public web at mytrt.app/learn/peptides and within the application. The My TRT App web reference also publishes 56 biomarker pages with clinical context, four laboratory and dosing calculators including a Vermeulen-equation free testosterone calculator, and seven long-form articles on hormone therapy topics. APPLE WATCH COMPANION The application includes a watchOS companion with one-tap dose logging and six complications, including a hematocrit complication that surfaces the most recent reading on the watch face. Elevated hematocrit (polycythemia) is among the more commonly monitored side effects of testosterone therapy. FOUNDER COMMENT "The category we set out to build for is patients who already do this work — who keep notes between draws and who chart their own trends," said Himanshu Batra, founder of Sphnix, Inc. and developer of My TRT App. "We wanted to provide a tool that matches that level of attention without putting the underlying data behind a clinic subscription." AVAILABILITY My TRT App is available on the Apple App Store and Google Play. A free tier includes dose logging, calendar tracking, and Apple Watch functionality. A subscription tier is available for users who require unlimited laboratory extraction and additional features. * iOS: https://apps.apple.com/app/my-trt-app/id6745529127 * Android: https://play.google.com/store/apps/details?id=com.batra.mytrtapp * Lab Snapshot Analyzer: https://www.mytrt.app/learn/tools/lab-snapshot * Peptide reference: https://www.mytrt.app/learn/peptides ABOUT MY TRT APP My TRT App is a TRT tracking app for iOS, Android, and watchOS, developed by Sphnix, Inc. The application was first released in 2025 and serves users tracking testosterone replacement therapy, hormone replacement therapy, peptide protocols, and GLP-1 medications. Himanshu Batra Sphnix, Inc +1 571-217-0000 hello@mytrt.app Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

WEDNESDAY, March 18, 2026 -- Among women using medically assisted reproduction (MAR), the overall incidence of cancer was comparable to that of the general population, according to a study published online March 10 in JAMA Network Open . Claire Melissa Vajdic, Ph.D., from University of New South Wales in Sydney, and colleagues compared cancer incidence in MAR-exposed women versus the general population of women. The analysis included 417,984 women (aged 18 to 55 years) who used MAR from 1991 to 2018 (assisted reproductive therapy [ART], 65.7 percent; intrauterine insemination with ovarian stimulation [IUI/OS], 28.9 percent; and ovulation induction using clomiphene citrate [clomiphene citrate], 42.0 percent). The researchers found that the overall incidence of invasive cancer was comparable with that of the general population for the ART and IUI/OS groups. Risk trended toward elevation for the clomiphene citrate cohort. Across all MAR exposures, the incidence rates of uterine cancer and in situ and invasive melanoma were higher, while lower incidence rates were seen for cervical cancer and cancer of the trachea, bronchus, and lung. For the ART and IUI/OS groups, ovarian cancer incidence was higher. Only the ART cohort had higher in situ breast cancer incidence, but the incidence of invasive breast cancer was not elevated. For invasive cancers with elevated incidence, rate differences were all small (<1 to 6.51 cases per 100,000 person-years). "Women who've had assisted fertility should continue to participate in routine cancer screening programs they’re eligible for," co-lead author Adrian Raymond Walker, Ph.D., also from University of New South Wales, said in a statement. "And they should discuss their cancer risk with their doctor, to understand how else they can reduce their risk." Several authors disclosed ties to the biopharmaceutical industry. Abstract/Full Text